A Study on Formulation and Assessment of Heart Rate Lowering Agent Ivabradine Orally Tablets

Abstract

This study aimed to develop a method for quantifying the amount of ivabradine in films that are ingested and administered with ease. To do this, a dry granulation technique was applied. The dry granulation process yielded good results when the F5 formulation was mixed with starch, anhydrous lactose, and microcrystalline cellulose PH 102. The strength of the tablet was modified by adding croscarmellose sodium. Sodium starch glycolate was used as the dissolving agent. Purified talc and colloidal silicon dioxide were utilised as glidents. In this mixture, magnesium stearate was employed as a lubricant. Purified talc was used to make tablets stronger and smoother, and titanium dioxide was used to make films opaque. Hydroxypropyl Methyl Cellulose 6 CPS was utilised as a film-forming agent, and polyethylene glycol 6000 was employed as a plasticizer. The manufactured tablet formulations were examined for friability (%), thickness, hardness, and disintegration time in addition to other medicinal properties. It was observed that the drug content was 99.94% and the in-vitro dissolution percentage was measured as 99.89%. Tablets coated with polymer film were manufactured by dry granulation. Ivabradine is administered to persons with coronary artery disease who have normal sinus rhythm and a heart rate more than 72 bpm in order to treat the symptoms of chronic stable angina pectoris. For the symptomatic treatment of stable angina pectorals and symptomatic eternal heart failure, ivabradine is a medication that reduces pulse rate.